secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-264748
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aardvark reports ARD-201 preserved lean mass, reduced weight; WE-868 shows >10% weight loss in mCRC patients
--------------------------------------------------------------------------------

- ARD-201 (ARD-101+sitagliptin) in DIO mice reduced body weight ~19% in 30 days, comparable to high-dose tirzepatide, and preserved lean mass.
- In Phase 2a, ARD-101 reduced hunger (CoEQ) and showed weight control signals, well-tolerated with no serious AEs in 14 adults with obesity.
- WE-868 (OxPhos modulator) induced >10% average weight loss in mCRC patients over median 10 weeks; in DIO mice, weight loss exceeded semaglutide at 50 mg/kg.
- Aardvark plans to start Phase 2 POWER trial (weight regain prevention) for ARD-201 by end 2025; investor webinar scheduled for Nov 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000119312525264748/0001193125-25-264748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000119312525264748/ck0001774857-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-264748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer